Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baum

Showing results (261-270 of 470) with videos related to

Pageof 47
Sort By:
World Journal of Gastroenterology|December 10, 2009
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumorDaniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 2, 2003
PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients' diagnostic and therapeutic managementPanagiota Mantaka, Richard P Baum, Andreas Hertel, et al.
Bioorganic & Medicinal Chemistry|March 10, 2007
Improved automated synthesis of [18F]fluoroethylcholine as a radiotracer for cancer imagingM Piel, A Bauman, R P Baum, et al.
European Journal of Clinical Investigation|December 1, 1986
Evaluation of low dose anaphylatoxic peptides in the pathogenesis of the adult respiratory distress syndrome (ARDS). Monitoring of early C5a effects in a guinea-pig in vivo model after i.v. applicationT Hoffmann, E C Böttger, H P Baum, et al.
Diagnostics (Basel, Switzerland)|August 26, 2022
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with <sup>177</sup>Lu-PSMA and Combined <sup>225</sup>Ac- and <sup>177</sup>Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic InvestigationThomas Langbein, Harshad R Kulkarni, Christiane Schuchardt, et al.
Nuklearmedizin. Nuclear Medicine|February 1, 1986
[Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis]M Lorenz, J Happ, C Hottenrott, et al.
Nuclear Medicine Communications|August 1, 1995
Validation of a dual-isotope technique using 123I-MIBG and 201Tl in the assessment of sympathetic reinnervation following heart transplantation: phantom and patient studiesB J Krause, C Gürtner, W T Kranert, et al.
HNO|September 1, 1994
[Immunoscintigraphy of carcinomas in the area of the head-neck with technetium-99m marked monoclonal antibody 174H.64. A new diagnostic procedure]J Kiefer, R P Baum, R Knecht, et al.
Annals of Surgery|October 8, 2020
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine NeoplasmsDaniel Kaemmerer, Matthias Twrznik, Harshad R Kulkarni, et al.
European Journal of Nuclear Medicine|September 2, 1998
Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findingsS Adams, R P Baum, A Hertel, et al.
Pageof 47

Showing results (261-270 of 470) with videos related to

Sort By:
Pageof 47
World Journal of Gastroenterology|December 10, 2009
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumorDaniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 2, 2003
PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients' diagnostic and therapeutic managementPanagiota Mantaka, Richard P Baum, Andreas Hertel, et al.
Bioorganic & Medicinal Chemistry|March 10, 2007
Improved automated synthesis of [18F]fluoroethylcholine as a radiotracer for cancer imagingM Piel, A Bauman, R P Baum, et al.
European Journal of Clinical Investigation|December 1, 1986
Evaluation of low dose anaphylatoxic peptides in the pathogenesis of the adult respiratory distress syndrome (ARDS). Monitoring of early C5a effects in a guinea-pig in vivo model after i.v. applicationT Hoffmann, E C Böttger, H P Baum, et al.
Diagnostics (Basel, Switzerland)|August 26, 2022
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with <sup>177</sup>Lu-PSMA and Combined <sup>225</sup>Ac- and <sup>177</sup>Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic InvestigationThomas Langbein, Harshad R Kulkarni, Christiane Schuchardt, et al.
Nuklearmedizin. Nuclear Medicine|February 1, 1986
[Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis]M Lorenz, J Happ, C Hottenrott, et al.
Nuclear Medicine Communications|August 1, 1995
Validation of a dual-isotope technique using 123I-MIBG and 201Tl in the assessment of sympathetic reinnervation following heart transplantation: phantom and patient studiesB J Krause, C Gürtner, W T Kranert, et al.
HNO|September 1, 1994
[Immunoscintigraphy of carcinomas in the area of the head-neck with technetium-99m marked monoclonal antibody 174H.64. A new diagnostic procedure]J Kiefer, R P Baum, R Knecht, et al.
Annals of Surgery|October 8, 2020
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine NeoplasmsDaniel Kaemmerer, Matthias Twrznik, Harshad R Kulkarni, et al.
European Journal of Nuclear Medicine|September 2, 1998
Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findingsS Adams, R P Baum, A Hertel, et al.
Pageof 47